<DOC>
	<DOCNO>NCT00290511</DOCNO>
	<brief_summary>The goal clinical research study learn chemotherapy give rituximab , follow Ibritumomab tiuxetan ( Zevalin ) , follow rituximab help control lymphoma . The safety treatment schedule also study . Objectives : 1 . To assess whether time progression high-risk patient prolong median 36 month , compare historical expectation approximately 24 month . 2 . To assess tolerance efficacy Y2B8 ( Zevalin ) R-FND ( rituximab , fludarabine , mitoxantrone , dexamethasone ) patient high-risk stage III-IV follicular lymphoma 3 . To assess overall response , failure-free survival , survival strategy compare historical experience FND ( fludarabine , mitoxantrone , dexamethasone ) alone R-FND 4 . To assess tolerance efficacy maintenance therapy rituximab . 5 . To maximize 12-month molecular remission rate patient high-risk stage III-IV follicular lymphoma 6. correlate result quantitative PCR assay classical PCR clinical outcome</brief_summary>
	<brief_title>Rituximab , Fludarabine , Mitoxantrone , Dexamethasone ( R-FND ) Plus Zevalin High-Risk Follicular Lymphoma</brief_title>
	<detailed_description>The treatment use program include several standard chemotherapy agent ( fludarabine , mitoxantrone , dexamethasone ) . Also , immune therapy agent give , include rituximab ( monoclonal antibody attack B-cells , type lymphoma make ) , Ibritumomab tiuxetan ( another similar monoclonal antibody , delivers radiation lymphoma cell strengthen attack ) . You receive rituximab Days 1 8 first cycle , Day 1 Cycles 2-4 monthly cycle chemotherapy , call R-FND . R-FND include rituximab fludarabine , mitoxantrone , dexamethasone . Fludarabine give 3 day , mitoxantrone 1 day , dexamethasone 5 day 28-day cycle ( FND ) . After 4 cycle R-FND , receive Ibritumomab tiuxetan . After Ibritumomab tiuxetan , receive rituximab every 2 month 1 year . All give vein . Sometimes dexamethasone give pill form . During study , blood test ( 2 tablespoon ) , sometimes every week . Every 2 cycle , chest x-ray CT scan abdomen pelvis . Bone marrow sample take . Heart function test do need . If desire , may possible receive study treatment home ( home doctor ) . Your study doctor discus possibility . If case , home doctor receive letter tell study ask wish participate treatment . He ask provide study doctor M. D. Anderson specific information treatment side effect may . All communication home doctor study doctor include part M. D. Anderson medical record . After study end , return checkup every 3 month first year , every 4 month Years 2 3 , every 6 month Years 4 5 . After , checkup need year . Blood ( 2 tablespoon ) bone marrow sample take visit . This investigational study . Ibritumomab tiuxetan rituximab approve FDA commercial use . The drug use study also approve commercial use FDA . About 50 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients highrisk Ann Arbor stage IIIIV follicular lymphoma . Highrisk define advanced stage ( III IV ) , plus 2 follow feature : age 60 great ; elevate LDH ; Hgb &lt; 12 ; number involve nodal site 5 . 2 . Patients previously untreated . 3 . Adequate organ function . 4 . Follicular lymphoma , grade 3 ( follicular large cell lymphoma ) : If eligible current large cell lymphoma protocol , alternative protocol recommend , particularly grade 3b FLCL patient characterize large noncleaved cell . However , FND rituximab establish efficacy FLCL , patient eligible protocol aggressive lymphoma ( e.g. , SCCL marrow ) , registration trial permit . 5 . Biopsy FNA material strongly recommend bcl2 study verify rearrangement status patient designate `` germline '' . ( see section 6.4 ) . For patient , tissue availability desirable mandatory . 6 . Patients must performance status Zubrod 3 well 7 . Patients must adequate renal hepatic function ( creatinine &lt; 2mg % ; bilirubin &lt; 2 mg % ) . Patients renal liver dysfunction due organ infiltration lymphoma may eligible discussion study chairman . 8 . Patients may receive concurrent chemotherapy , radiotherapy , immunotherapy . 9 . Patients must sign informed consent indicate aware investigational nature study keep policy hospital . 1 . Patients unable unlikely able adhere treatment plan return Houston followup visit geographical , economic , emotional , social consideration eligible study . Note : followup care may provide outside physician long MDACC protocol outside physician participation strictly adhere . 2 . Patients absolute peripheral granulocyte count &lt; 1,000 platelet count &lt; 100,000 unless due marrow infiltration hypersplenism . 3 . Patients organ dysfunction , include bilirubin &gt; 2 mg % serum creatinine level &gt; 2 mg % , unless alteration due lymphoma . 4 . Patients HIV infection register protocol . 5 . Patients antecedent malignancy whose prognosis poor ( &lt; 90 % probability survive 5 yr ) . 6 . All patient cardiac ejection fraction 50 % echocardiography MUGA . 7 . Patients accept transfusion blood product supportive care measure antibiotic eligible study . 8 . Female patient must pregnant lactating , men woman reproductive potential must follow accept birth control method . 9 . Patients receive prior murine antibody therapy exclude . 10 . Patients evidence active prior infection Hepatitis B exclude . ( Note : Persons vaccinate Hepatitis B + antibody exclude ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Ibritumomab Tiuxetan</keyword>
	<keyword>IDEC-Y2B8</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludara</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>R-FND</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Decadron</keyword>
</DOC>